Abivax SA (FR:ABVX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abivax SA has reported its share capital and voting rights as of April 30, 2024, revealing a total of 62,930,818 shares and 69,931,576 theoretical voting rights. The number of exercisable voting rights stands at 69,920,692. Abivax, a clinical-stage biotech firm, is progressing with phase 3 clinical trials of its lead drug candidate for ulcerative colitis.
For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.
